FSAGX
Price
$60.12
Change
+$0.70 (+1.18%)
Updated
Jun 2 closing price
Net Assets
4.23B
INIYX
Price
$29.25
Change
+$0.38 (+1.32%)
Updated
Jun 2 closing price
Net Assets
1.55B
Interact to see
Advertisement

FSAGX vs INIYX

Header iconFSAGX vs INIYX Comparison
Open Charts FSAGX vs INIYXBanner chart's image
FSAGX vs INIYX Comparison Chart in %
View a ticker or compare two or three
VS
FSAGX vs. INIYX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSAGX is a Hold and INIYX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSAGX has more cash in the bank: 4.23B vs. INIYX (1.55B). INIYX pays higher dividends than FSAGX: INIYX (5.44) vs FSAGX (4.78). FSAGX was incepted earlier than INIYX: FSAGX (40 years) vs INIYX (16 years). INIYX (1.03) is less costly to investors than FSAGX (0.64). FSAGX is a more actively managed with annual turnover of: 60.00 vs. INIYX (30.00). FSAGX has a lower initial minimum investment than INIYX: FSAGX (0) vs INIYX (1000). INIYX annual gain was more profitable for investors over the last year : 76.16 vs. FSAGX (59.65). INIYX return over 5 years is better than : 167.03 vs. FSAGX (112.60).
FSAGXINIYXFSAGX / INIYX
Total Expense Ratio0.641.0362%
Annual Report Gross Expense Ratio0.641.0362%
Fund Existence40 years16 years-
Gain YTD4.1686.41465%
Front LoadN/AN/A-
Min. Initial Investment01000-
Min. Initial Investment IRAN/AN/A-
Net Assets4.23B1.55B273%
Annual Yield % from dividends4.785.4488%
Returns for 1 year59.6576.1678%
Returns for 3 years174.99225.7978%
Returns for 5 years112.60167.0367%
Returns for 10 years205.37328.0263%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHOO44.261.08
+2.50%
Steven Madden Ltd
PHR10.36-0.30
-2.81%
Phreesia
RCI38.22-1.11
-2.82%
Rogers Communications
GOAI3.18-0.10
-3.05%
Eva Live Inc.
APVO5.02-0.22
-4.20%
Aptevo Therapeutics Inc